Modulation of the immune system by the gut microbiota in the development of type 1 diabetes. Issue 11 (2nd November 2018)

• Record Type: Journal Article
• Authors: Pearson, James A.; Agriantonis, Andrew; Wong, F. Susan; Wen, Li
• Is Part Of: Human vaccines & immunotherapeutics. Volume 14:Issue 11(2018)
• Page Start: 2580
• Page End: 2596
• Publication Date: 2018-11-02
• Subjects: Gut microbiota -- type 1 diabetes -- NOD mice -- therapy; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2018.1514354
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: T1D is an autoimmune disease characterized by T cell-mediated destruction of insulin-producing β-cells in the pancreatic islets of Langerhans, resulting in hyperglycemia, with patients requiring lifelong insulin treatment. Many studies have shown that genetics alone are not sufficient for the increase in T1D incidence and thus other factors have been suggested to modify the disease risk. T1D incidence has sharply increased in the developed world, especially amongst youth. In Europe, T1D incidence is increasing at an annual rate of 3–4%. Increasing evidence shows that gut microbiota, as one of the environmental factors influencing diabetes development, play an important role in development of T1D. Here, we summarize the current knowledge about the relationship between the microbiota and T1D. We also discuss the possibility of T1D prevention by changing the composition of gut microbiota.